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Background: Staphylococcus aureus is one of the most common and lethal causes of bloodstream infection and
the incidence is increasing. We carried out a prospective observational study of patients with Staphylococcus aureus
bloodstream infection and sepsis in Nord-Trøndelag county in Norway from 1996–2011. The main outcome of interest
was all-cause mortality within 30 and 90 days.
Methods: Positive blood cultures were registered prospectively by the microbiology laboratory and clinical variables
were retrospectively registered from patients’ hospital records. The severity of sepsis was assigned according to the
2001 International Sepsis Definition Conference criteria. The association between clinical characteristics and mortality
was studied using logistic regression analysis, and adjusted 30- and 90-day mortality risks were estimated.
Results: Among 373 patients, the median age was 74 years and 60.3% were male. 0.8% of the patients were
diagnosed with MRSA. 29.8% of the patients developed severe sepsis and 12.9% developed septic shock. The all-cause
mortality was 14.5%, 27.3% and 36.2% at 7, 30 and 90 days, respectively. Compared to patients with sepsis without
organ failure (Mortality risk 13.3%, 95% CI 7.5-16.3%), the 30-day mortality risk was 3-fold higher among those
with severe sepsis (39.9%, 95% CI 29.5-48.5%) and more than 4-fold higher for those with septic shock (57.3%,
95% CI 42.5-72.2%). The 30-day all-cause mortality varied by focus of infection, with the highest 30-day mortality
risk among those with a pulmonary focus (42.4%, 95% CI 26.0-58.5%) and unknown focus of infection (38.7%,
95% CI 27.5-48.2%). The mortality risk did not differ between the first and second halves of the study period
with a 30-day mortality risk of 27.3%, (95% CI 18.1-33.1%) for 1996–2003 versus 27.4% (95% CI 19.4-31.4%) for
2004–2011. The same pattern was seen for 90-day mortality risk.
Conclusion: Staphylococcus aureus bloodstream infection carries a high case fatality rate, especially among
those with severe sepsis and septic shock and among those with a pulmonary or unknown focus of infection.
There was no decrease in 30- or 90-day mortality risk during the study period. This underscores the importance
of continuing surveillance and efforts to improve the outcome of this serious disease.
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Staphylococcus aureus is one of the most lethal and com-
mon causes of bloodstream infection, with an incidence
of 26/100 000 population/year [1]. Of concern, a 34%
increase in incidence has been observed in Europe from
2002–2009 [2]. Factors contributing to the role of
Staphylococcus aureus as a public health problem in-
clude its affinity to foreign objects such as intravenous
lines and prosthetic material, and its propensity to gen-
erate metastatic foci and complicated disease [3]. An-
other challenge is its ability to quickly develop resistance
to antimicrobial agents [4]. Even in populations with a
low level of antibiotic resistance, Staphylococcus aureus
is a cause of severe bloodstream infection with high
mortality [5]. Despite improvements in survival over the
last three decades, the 30 day all-cause mortality rates
are still at 17-39% [5-10].
Several studies have shown that the outcome of
Staphylococcus aureus bloodstream infection may differ
by focus of infection, with unidentified focus, respiratory
focus and endocarditis being associated with the highest
mortality [8]. In addition, an uneradicated or non-
eradicable focus has been associated with increased mor-
tality [11,12]. Older age, increasing number and types of
comorbid diseases before the onset of infection and clin-
ical severity of the bloodstream infection have also been
associated with reduced survival [13].
The clinical characteristics and outcome of Staphylo-
coccus aureus bloodstream infection are well described
in many Western countries [8,14]. However, it is im-
portant to study the clinical outcome of bloodstream
infections in multiple populations and at multiple time
points both to evaluate differences in disease charac-
teristics between populations and to gauge the devel-
opment over time. It is important to investigate the
characteristics of the disease in order to identify areas
where management can be improved. Internationally,
there has been an increasing effort to improve the
management and outcome of sepsis including blood-
stream infection over the last decades with initiatives
such as the international Surviving Sepsis Campaign
[15,16]. In order to improve follow up and treatment of
this patient group we carried out a prospective observa-
tional study of Staphylococcus aureus bloodstream infec-
tion in Nord-Trøndelag County.
Methods
Setting and population
Nord-Trøndelag is a county in Central Norway with a
current population of 134 864. It is served by two
community hospitals, Namsos Hospital and Levanger
Hospital. The closest tertiary referral hospital is St
Olavs University Hospital in Trondheim. We included
all patients ≥ age 16 diagnosed with Staphylococcusaureus bloodstream infection at Levanger Hospital be-
tween 1996 and 2011, and at Namsos Hospital
between 1999 and 2011. For residents of Nord-
Trøndelag who in 1995–97 had participated in a
population survey (the HUNT2 survey) we could also
include infections detected at St. Olavs Hospital be-
tween 1996 and 2011. All adults in Nord-Trøndelag
were invited to the survey and 69.5% participated
[17]. All positive blood cultures have been prospect-
ively registered by the clinical microbiology laboratory
in Levanger, Namsos and at St. Olavs Hospital. BAC-
TEC 9240 (Becton Dickinson Diagnostic Instrument
Systems, Sparks, MD) was used for blood culture
testing [18]. Resistance testing was performed by disc
diffusion. Methicillin resistance was tested with a
cefoxitin disc. Oxacillin-resistant isolates were sent to
St Olavs Hospital for testing of the mecA gene.Patient characteristics
Clinical information was gathered retrospectively from
the patients’ hospital records. All data were collected
using a standardized data retrieval form assessing
patient characteristics, comorbid conditions, results of
investigations and treatment. The data collection was
carried out by trained research nurses and all regis-
tered data was secondarily assessed either by an infec-
tious disease consultant or the first author of this
study. An episode of bloodstream infection was defined
as the presence of one or more microorganism(s) in
blood culture along with clinical evidence of infection. If
a patient had more than one episode of Staphylococcus
aureus bacteremia during the study period, only the first
was included. We decided to include patients with poly-
microbial infection in this study since a bloodstream
infection containing Staphylococcus aureus should be
regarded as clinically significant [19].
The setting of infection was classified as hospital-
acquired (HA), healthcare-associated (HCA) or com-
munity-acquired (CA) as defined by Friedman et al.
[20], with the exception that only patients that were
hospitalized for two or more days in the 30, as op-
posed to 90 days prior to the infection were classified
as having a HCA infection, in keeping with the defi-
nition used by Shorr et al. [21]. The number and se-
verity of combined comorbid conditions were assessed
according to the Charlson weighted Comorbidity
Index (CCI) [22]. Mortality was measured as all-cause
mortality within day 7, 30 and 90. By using the 11-
digit unique identification number of all Norwegian
citizens, electronic hospital records in Norway are
updated with mortality data from the Norwegian
population registry so that mortality data after dis-
charge from hospital can be reliably assessed.
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We graded the severity of disease (sepsis, severe sepsis
and septic shock) according to the 2001 International Sep-
sis Conference definition [15]. In our cohort we defined
sepsis as documented bloodstream infection and two or
more of the following: temperature ≥38.3°C or < 36.0°C,
heart rate >90 beats/minute, respiratory rate >20/min or
PaCO2 < 4.3 kPa or mechanical ventilation due to acute
respiratory failure, glucose >7.7 mmol/l in the absence of
diabetes, leucocytes >12 × 109/l or < 4 × 109/l, elevated
CRP or procalcitonin, acute hypotension (systolic BT
<90 mmHg, MAP <70 mmHg or a fall of ≥ 40 mmHg), or
significant positive fluid balance (>20 ml/kg over 24 hours).
Severe sepsis was defined as sepsis and sepsis-related
dysfunction in at least one organ, or hypoperfusion or
hypotension. Acute organ dysfunction was defined as
mental confusion, arterial hypoxemia, acute oliguria,
increase in serum creatinine of ≥ 45 μmol/l, low platelet
count, coagulation disturbance, ileus, or hyperbilirubine-
mia. The specific criteria for organ dysfunction used
were the same as those outlined in the 2001 Inter-
national Sepsis Conference definition [15].
Septic shock was defined as sepsis and systolic blood
pressure <90 mmHg or a fall in systolic blood pressure
of at least 40 mmHg despite at least 1000 ml fluid resus-
citation or vasopressor needed to maintain systolic blood
pressure >90 mmHg and evidence of organ failure.
Any alteration in disease severity was registered, and
the timing and extent of the most pronounced degree of
organ dysfunction was noted and used to define whether
the patient had sepsis, severe sepsis or septic shock. For
those who did not show any evidence of deterioration
during the episode, the day of positive blood culture was
registered as the day with the most severe affection. Se-
verity of disease was also assessed by the Pitt bacteremia
score [23].Focus of infection
Reported signs of infection along with focal growth of
the same microbe as in blood culture was taken as a
confirmation of skin, soft tissue, joint or surgical infec-
tion. Respiratory focus was diagnosed with clinical signs
of respiratory infection accompanied by positive radio-
logic findings. Intravenous line infection was diagnosed
with growth of Staphylococcus aureus from the tip of the
catheter as well as in peripheral blood, and also if the
microbe was isolated from pus around the catheter entry
site. If clinical signs of catheter infections were present
without local growth and no other focus was detected
an intravenous line infection was registered as likely.
Staphylococcus aureus has also been shown to be a likely
ascending urinary pathogen among patients with urinary
tract catheterization or manipulation [24,25]. A urinaryfocus was assigned when there was growth of bacteria in
the urine as well as in blood along with clinical signs/
symptoms or risk factor for urinary infection, and no
other source of infection was identified. Endocarditis was
registered if diagnosed according to clinical and echocar-
diographic criteria during the hospital stay. An unknown
focus of infection was assigned when none of the criteria
for ascertaining a focus were met.Management
Empiric antibiotic treatment was defined as treatment
given before the pathogen was known. Definitive treat-
ment was defined as treatment administered after result
of the blood cultures was available. Inefficient antibiotic
treatment was defined as treatment to which the mi-
crobe was resistant. Treatment was defined as efficient
as long as the microbe was sensitive, even if the drug
administered was not the first choice.Ethical considerations
The study was approved by the Central Norway Regional
Committee for Medical Health and Research Ethics.
Since no patient contact or intervention was carried out,
the need for informed consent was waived.Statistical analysis
Data was analyzed using SPSS for Windows (Version
21, Armonk, NY: IBM Corp) and STATA version 13
(StataCorp LP, College Station, Texas). The associa-
tions between clinical characteristics and 30- and 90-day
mortality were investigated using logistic regression ana-
lysis where odds ratios (ORs) with 95% confidence inter-
vals (CIs) were estimated. In addition, we studied the
association between clinical characteristics and severe
sepsis/septic shock as an outcome, in order to identify
groups of patients particularly vulnerable to develop
severe disease and need a higher level of follow-up and
care. All associations were estimated both unadjusted
and adjusted for potential confounders. Thus, all analyses
were adjusted for sex and age group (<60, 60–69, 70–79
and ≥80 years). For place of acquisition, focus, severity
and time period, the associations were additionally
adjusted for prior comorbid conditions using three cat-
egories of the CCI (0, 1–2 and ≥3). For the association
between individual comorbid conditions and 30- and 90-
day mortality, those not having the condition in question
were used as reference. Adjusted 30- and 90-day mortal-
ity risks and risk of severe sepsis/shock were estimated
from the logistic regression model. For ordinal variables,
we tested for linear trend across categories by using the
categories as a continuous variable in the logistic regres-
sion analysis.
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We identified 402 episodes of Staphylococcus aureus
bloodstream infection during the study period, of which
23 were recurrent episodes. Six patients did not meet
the clinical criteria for sepsis, either because of a mild
clinical course with only one elevated inflammatory par-
ameter or because clinical or laboratory data needed to
assess whether these patients met the sepsis criteria were
lacking. For this reason we chose to exclude these
patients thus leaving 373 patients for further analysis. 25
patients (6.7%) had polymicrobial infection. 3 patients (0.8%)
were diagnosed with MRSA, 2 of these were in the setting
of a polymicrobial infection and all three episodes were
healthcare-associated. Data on antibiotic susceptibility
were available for the 348 monomicrobial isolates. 26.7%
were penicillin-sensitive, 99.4% were dicloxacillin-sensitive,
98.5% were gentamicin-sensitive (Table 1).
The median patient age was 74 years, 60.3% of the
cases were male. Overall, 41.8% acquired the infection
in a healthcare-associated setting (HCA), 29.2% were
hospital-acquired (HA) and 29.0% were community-
acquired (CA). Previously known comorbid illness
was present in 94.6% of the patients (Table 1). The
all-cause mortality rate was 14.5%, 27.3% and 36.2%
at 7, 30 and 90 days, respectively (Table 2).
The 30-day mortality risk differed by age and by num-
ber and severity of comorbid conditions prior to the on-
set of infection. Compared to those having CCI score of
0 (30-day mortality risk 13.7%, 95% CI 7.0-21.8%), the
30-day mortality risk was 2-fold higher among those
with CCI score 1–2 (24.8%, 95% CI 17.6-31.0%) and 3-
fold higher for those with CCI score of 3 or more
(39.1%, 95% CI 30.0-47.6%) (Table 3). The number and
severity of comorbid conditions were similarly associated
with 90-day mortality risk (Additional file 1: Table S1).
57.4% of the patients had sepsis with no organ failure,
29.8% had severe sepsis and 12.9% had septic shock
(Table 2). Compared to those with sepsis without organ
failure (30-day mortality risk 13.3%, 95% CI 7.5-16.3%),
the 30-day mortality risk was 3-fold higher among those
with severe sepsis (39.9%, 95% CI 29.5-48.5%) and more
than 4-fold higher for those with septic shock (57.3%,
95% CI 42.5-72.2%) (Table 4). A similar association was
seen with 90-day mortality risk (Additional file 1: Table
S2). A steady increase in mortality risk according to
severity was also observed for the Pitt bacteremia score.
The focus of infection was ascertained in 74.5% of the
patients, whereas in 25.5%, no focus was identified. The
most common focus was skin and soft tissue infections
(19.6%), whereas 4.8% were diagnosed with endocarditis.
Overall, 35.9% of the patients were assessed with echo-
cardiography (Table 2). Among those with no ascertained
focus of infection, 29.8% were examined with echocardi-
ography. The mortality varied by focus of infection. Thehighest 30-day mortality risk was seen among those with a
respiratory focus (42.4%, 95% CI 26.0-58.5%) and un-
known focus of infection (38.7%, 95% CI 27.5-48.2%)
(Table 4). The highest 90-day mortality risk was seen for
the same foci (Additional file 1: Table S2). The lowest 30-
day risk was seen for urinary tract focus (11.2%, 95% CI
3.4-24.0%), abscess (15.6%, 96% CI 4.3-35.4%), and osteo-
myelitis/septic arthritis (13.8%, 95% CI 4.9-26.1%) (Table 4).
For these foci there was also a low risk at 90 days
(Additional file 1: Table S2). The mortality risk for
patients with endocarditis was low at 30 days (13.4%,
95% CI 2.8-37.4%) (Table 4), but the risk increased
nearly three-fold to 39.3% at 90 days (95% CI 17.0-
63.7%) (Additional file 1: Table S2).
Overall, 24.7% of the patients were treated in the
intensive care unit or a medical high dependency unit.
Among those with septic shock 79.2% were admitted to
the ICU or medical high dependency unit, whereas
30.6% of those with severe sepsis received care at the
ICU or medical high dependency unit. The risk of
acquiring severe sepsis/septic shock increased with age
from 30.7% (95% CI 21.7-41.6%) for those aged < 60 to
49.0% (95%CI 40.3-57.7%) for those aged ≥80. Among
individual comorbidities the risk of severe sepsis or sep-
tic shock was highest for those with heart failure (67.4%,
95% CI 51.2-80.6%), renal failure (60.5%, 95% CI 45.3-
73.9) and chronic pulmonary disease (55.6%, 95% CI
43.0-67.6%). The infectious foci associated with the high-
est risk of developing severe disease included endocardi-
tis (86.0%, 95% CI 64.4-95.8%), respiratory focus (52.4%,
95% CI 36.2-68.1%) and unknown infectious foci (51.0%,
95% CI 40.6-61.3%) (Additional file 1: Table S3).
The most common empirical antibiotic regimens ad-
ministered were penicillin combined with an aminogly-
coside (17.3%), cefuroxime-containing regimens (16.9%)
and dicloxacillin-containing regimens (16.6%). 2.9% re-
ceived no initial treatment. 15.3% received initial treat-
ment that was not effective against the microbe in
question, and most of these were treated with penicillin
in monotherapy. As definitive treatment, 51% of the
patients were treated with dicloxacillin-containing regi-
mens. 2.7% received no definitive treatment and 2.9%
received inefficient definitive treatment (Table 2).
Among those with community-acquired infection, 31
patients (28.7%) received inefficient or no treatment
initially. The same was true for 16.7% of those with
healthcare-acquired infection and 10.1% of those with
hospital-acquired infection. 119 patients, (31.9%) re-
ceived surgical treatment including drainage of abscesses
and pleural fluid, wound revisions, amputations, arthro-
centesis, removal of orthopedic hardware, stenting of the
renal pelvis or the common bile duct and cardiac valve
surgery. The median duration of intravenous antibiotic
therapy was 10 days and the meadian total duration
Table 1 Patient and infection characteristics
Characteristic N (%)
Patients included 373 (100)
Sex
Female 148 (39.7)
Male 225 (60.3)
Acquisition
Community-acquired 108 (29.0)
Healthcare-associated 156 (41.8)
Hospital-acquired 109 (29.2)
Age category
<60 81 (21.7)
60-69 58 (15.6)
70-79 109 (29.2)
≥80 125 (33.5)
Comorbid conditions
No underlying illness 20 (5.4)
Malignancy 96 (25.7)
Renal failure 45 (12.1)
Diabetes mellitus 72 (19.3)
Hypertension 114 (30.6)
Cardiovascular disease 154 (41.3)
Heart failure 40 (10.7)
Chronic pulmonary disease 62 (16.6)
Rheumatic disease 39 (10.5)
Charlson Comorbidity Index (CCI)
0 85 (22.8)
1-2 160 (42.9)
≥3 128 (34.3)
Focus of infection
Unknown 94 (25.2)
Respiratory focus 37 (9.9)
Urinary tract 33 (8.8)
Skin/soft tissue 73 (19.6)
Abscess 27 (7.2)
IV catheter 28 (7.5)
Endocarditis 18 (4.8)
Osteomyelitis/Septic arthritis 44 (11.8)
Other* 19 (5.1)
Microbiological characteristics
Polymicrobial infection 25 (6.7)
Methicillin-resistant isolates 3 (0.8)
Penicillin-sensitive isolates§ 93 (26.7)
Dicloxacillin-sensitive isolates§ 346 (99.4)
Gentamicin-sensitive isolates§$ 323 (98.5)
Gentamicin intermediate or resistant§$ 5 (1.5)
Table 1 Patient and infection characteristics (Continued)
Time period
1996-2003 144 (38.6)
2004-2011 229 (61.4)
*Other focus includes dental foci, parotitis, 2 cases of meningitis, mediastinits,
an infected peritoneal dialysis catheter and one probable intravascular graft
infection.
§assessed for monomicrobial episodes, n = 348.
$Data lacking for 20 isolates (5.7%).
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When examining the first (1996–2003) and second
(2004–2011) halves of the study separately, 30.6% of the
patients in the first period and 32.8% of the patients in
the second period received surgical treatment. 32.6% of
the patients in the first period were examined with echo-
cardiography versus 38.0% in the second period of the
study.
This study was carried out over a period of 16 years.
The age, sex and comorbidity-adjusted 30-day mortal-
ity risk did not differ between the first and second
halves of the study period with an adjusted mortality
risk of 27.3% (95% CI 18.1-33.1%) for 1996–2003 ver-
sus 27.4% (95% CI 19.4-31.4%) for 2004–2011 (Table 4).
The same pattern was seen for 90-day adjusted mor-
tality risk (Additional file 1: Table S2).Discussion
This study highlights several important aspects regard-
ing bloodstream infection and sepsis with Staphylococcus
aureus. Only 6 patients out of 379 with positive blood
cultures did not meet the criteria for sepsis, emphasizing
the clinical relevance of a positive blood culture for
Staphylococcus aureus. Our findings also confirm that
the proportion of Staphylococcus aureus bloodstream
infections caused by MRSA in Norway is low. There was
a strong influence of age, comorbid burden, disease
severity and focus of infection on the outcome, and
there was a stable high case fatality rate of 27.3% during
the study period. Our 30 day all-cause mortality rate is
higher than in other Scandinavian studies [7,26], but a
clinical study of Staphylococcus aureus bacteremia in
inpatients in Oxfordshire and one German study found
similar mortality rates [27,28]. Some of these differences
could be due to differences in study design and patient
characteristics. One factor contributing to the high mor-
tality rate in our population could be the old age of our
patients. We also found a clear association between
comorbid diseases and mortality, and a high proportion
of our patients suffered from comorbid disease. The
association between an increased CCI and mortality in
patients with Staphylococcus aureus bacteremia has been
shown earlier by Lesens et al. [29].
Table 2 Patient outcomes and management
Severity of sepsis N (%)
Sepsis without organ failure 214 (57.4)
Severe sepsis 111 (29.8)
Septic shock 48 (12.9)
Pitt bacteremia score
0 127 (34.0)
1 115 (30.8)
2 65 (17.4)
≥3 66 (17.7)
All-cause mortality
7-day 54 (14.5)
30-day 102 (27.3)
90-day 135 (36.2)
Empiric antibiotic management
Penicillin plus aminoglycoside 65 (17.3)
Cefuroxime-containing regimens 63 (16.9)
Dicloxacillin-containing regimens 62 (16.6)
Penicillin monotherapy 52 (13.9)
Cefotaxime-containing regimens 47 (12.7)
Other treatment 73 (19.6)
No treatment 11 (2.9)
Inefficient treatment 57 (15.3)
Definitive antibiotic treatment*
Penicillin plus aminoglycoside 18 (4.8)
Dicloxacillin-containing regimens 190 (51.0)
Penicillin monotherapy 34 (9.1)
Cefuroxime-containing regimens 29 (7.9)
Cefotaxime-containing regimens 28 (7.6)
Other treatment 62 (16.7)
No treatment 10 (2.7)
Inefficient treatment 11 (2.9)
Median antibiotic treatment duration
(interquartile range)$
Intravenous treatment (N = 351) 10 days (5–15)
Total antibiotic treatment duration (N = 331) 14 days (10–25)
Aminoglycoside treatment (N = 117) 3 days (2–7)
Other management
Received surgical treatment 119 (31.9)
Treatment in Intensive Care Unit (ICU)/High
dependency unit
92 (24.7)
Treatment with vasopressors 39 (10.5)
Ventilator treatment 15 (4)
Examined with echocardiography 134 (35.9)
Median length of stay (interquartile range) 13 days (7–22)
*Data on definitive treatment lacking for two patients.
$Data is lacking on 22 patients for intravenous treatment duration and on 42
patients for total antibiotic treatment duration.
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sis or septic shock during their episode, with a striking
accompanying increase in mortality even when adjusting
for age, sex and comorbid burden. This strong associ-
ation has been observed in several other studies [13].
The same pattern was seen for severity classified by the
Pitt bacteremia score, with increased mortality for
patients with a score of 2 or more. Pitt bacteremia score
has been shown to be significantly correlated with mor-
tality both in prospective clinical and ICU based trials
[30,31]. In our cohort, nearly 70% of those with severe
sepsis and 20% of those with septic shock were treated
on a general hospital ward. Although care at a regular
bed unit can be of very high quality and there can be
various good reasons for not increasing the level of care
for example a palliative setting, this still highlights the
importance of well-established routines to identify and
follow up these patients and ensure the best standard of
care.
Assigning focus of infection of Staphylococcus aureus
is challenging because of the organism’s affinity to for-
eign objects and its propensity to generate metastatic
foci [3]. We found a high mortality among patients with
an unknown focus of infection. This is in line with
results from previous studies [8,32]. The importance of
ascertaining a focus of infection and removing it if pos-
sible has been well established [19]. We found lower
mortality among those with bone and joint infection,
abscess and primary urinary focus. The two latter can
possibly be explained by the possibility to promptly
remove the focus of infection in most cases. Bacteriuria
accompanying Staphylococcus aureus bloodstream infec-
tion has been seen as a sign of hematogenous spread of
infection with higher mortality, but ascending infection
is also possible and has been linked to a more favorable
outcome [6,24,33,34]. Surprisingly, we also found a low
30-day mortality of endocarditis of 13.4% in our patient
cohort, but this was increased by a three-fold by day 90
to 39.3%. We do not have a definite explanation for this
difference in short and longer term mortality, but more
intensive follow-up and management in the initial
phases of the disease as well as ongoing damage to
valves and endocardial structures may be contributing
factors. Overall, we had a low proportion of endocarditis
of 4.8% in our cohort. This is lower than the 8.3% found
by Kaasch et al. in a recent pooled analysis of 5 pro-
spective observational studies [8] and much lower than a
recent multicenter study in Denmark where 22% of the
patients screened with echocardiography were diagnosed
with endocarditis [35]. One possible explanation of the
low prevalence in our cohort is underdiagnosis due to
the low rate of examination with echocardiography.
Rasmussen et al. identified an unknown focus of in-
fection as one of several independent risk factors for
Table 3 30-day mortality in relation to patient characteristics prior to infection
Age- and sex-adjusted
Characteristic No. of deaths
within 30 days
30-day mortality
within category (%)
Odds ratio 95% CI p Mortality risk (%) 95% CI (%)
Age (years)
<60 11 13.6 1 Reference 13.6 7.7-23.0
60-69 15 25.9 2.21 0.93-5.26 0.07 25.9 16.2-38.6
70-79 27 24.8 2.09 0.97-4.52 0.06 24.8 17.6-33.8
≥80 49 39.4 4.04 1.95-8.40 <0.001 38.9 30.8-47.8
p for trend <0.001
Sex
Male 57 25.3 1 Reference 25.9 19.4-30.9
Female 45 30.4 1.21 0.75-1.94 0.43 29.5 21.6-36.4
Charlson Comorbidity Index (CCI)
0 11 12.9 1 Reference 13.7 7.0-21.8
1-2 41 25.6 2.13 1.02-4.48 0.05 24.8 17.6-31.0
≥3 50 39.1 4.29 2.01-9.14 <0.001 39.1 30.0-47.6
p for trend <0.001
Comorbidities$
Malignant disease 26 27.1 0.97 0.57-1.66 0.91 26.9 17.8-35.5
Renal failure 19 42.2 2.18 1.11-4.27 0.02 41.5 27.1-56.3
Diabetes mellitus 21 29.2 0.99 0.56-1.80 >0.99 27.3 17.2-37.5
Hypertension 36 31.6 1.15 0.69-1.91 0.6 29.1 20.3-37.3
Cardiovascular disease 51 33.1 1.29 0.78-2.11 0.32 30.0 22.0-37.2
Heart failure 20 50.0 2.4 1.21-4.80 0.01 43.8 28.7-59.5
Chronic pulmonary disease 25 40.3 2.01 1.12-3.62 0.02 39.2 27.0-51.4
Rheumatic disease 15 38.5 1.84 0.90-3.78 0.09 38.5 23.6-54.3
$Those not having the condition in question were used as reference category for each individual comorbidity studied in this analysis.
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aureus bacteremia, and only 29.8% of our patients
with unknown focus were examined with echocardiog-
raphy. It is possible that some of the patients without
ascertained focus of infection had endocarditis. Underdi-
agnosis of endocarditis may lead to inadequate manage-
ment including antibiotic treatment, and may be one
factor explaining the rather high case-fatality rate in this
study. The higher case-fatality rate among those with an
unknown focus of infection may be due to a reluctance
to carry out investigations on patients where the overall
prognosis is unfavorable, such as end-of life situations.
On the other hand the low performance of echocardiog-
raphy and the increased case-fatality rate may also indi-
cate that fairly simple improvements in clinical standards
of assessment may help strengthen the diagnostic accur-
acy, treatment and hopefully outcome for this patient
group.
The prevalence of MRSA in this cohort was low, and
most patients received adequate antibiotic management,
especially after the microbe was identified. Interestingly,nearly a third of those with community-acquired infection
received inadequate therapy, often penicillin in mono-
therapy. This is probably a sign that the level of suspicion
for this pathogen is lower than for patients that contract
this infection in a healthcare-associated setting. Delay of
adequate treatment is of clinical importance because of
the associated increased risk of infection-related mortality
[36]. There were standardized local procedures available
for treating sepsis with an unknown microbe and focus,
primarily recommending the use penicillin and an amino-
glycoside such as gentamicin, tobramicin or netilmicin.
There was no standardized guideline available for the
management of Staphylococcus aureus bloodstream infec-
tion specifically, but national guidelines recommended
dicloxacillin as the preferred antibiotic to treat Staphylo-
coccus aureus infections [37]. The management of the
patients and choice of treatment was at the discretion of
the managing physician, as was the decision of referral to
an infectious disease specialist. There was no specific
local guideline recommending echocardiography for pa-
tients with Staphylococcus aureus bloodstream infections,
Table 4 30-day mortality in relation to disease acquisition, severity, focus and time period
Age-, sex- and comorbidity-adjusted
Characteristic No. of deaths
within 30 days
30-day mortality
within category (%)
Odds ratio 95% CI p Mortality risk (%) 95% CI
Place of acquisition
Community-acquired 22 20.4 1 Reference 24.2 14.3-31.5
Healthcare-associated 48 30.8 1.18 0.62-2.23 0.61 27.1 18.2-32.5
Hospital-acquired 32 29.4 1.42 0.72-2.78 0.31 30.5 20.2-37.9
Severity
Sepsis without organ failure 27 12.6 1 Reference 13.3 7.5-16.3
Severe sepsis 45 40.5 4.97 2.77-8.93 <0.001 39.9 29.5-48.5
Septic shock 30 62.5 10.98 5.16-23.35 <0.001 57.3 42.5-72.2
p for trend <0.001
Pitt bacteremia score
0 26 20.5 1 Reference 20.3 12.0-25.7
1 22 19.1 0.97 0.49-1.88 0.92 19.8 11.3-25.6
2 21 32.3 2.30 1.13-4.79 0.02 35.5 22.6-46.7
≥3 33 50.0 3.66 1.85-7.23 <0.001 45.1 31.9-57.3
p for trend <0.001
Focus of infection
Unknown 40 42.6 1 Reference 38.7 27.5-48.2
Respiratory focus 16 43.2 1.18 0.52-2.70 0.69 42.4 26.0-58.5
Urinary tract 4 12.1 0.18 0.05-0.57 0.004 11.2 3.4-24.0
Skin/soft tissue 21 28.8 0.57 0.29-1.14 0.11 27.6 16.5-37.1
Abscess 3 11.1 0.26 0.07-1.00 0.05 15.6 4.3-35.4
Intravenous catheter 6 21.4 0.37 0.13-1.05 0.06 20.3 7.8-36.3
Endocarditis 2 11.1 0.22 0.04-1.07 0.06 13.4 2.8-37.4
Osteomyelitis/Septic arthritis 5 11.4 0.23 0.08-0.67 0.007 13.8 4.9-26.1
Other focus 5 26.3 0.63 0.2-2.0 0.43 29.4 11.4-52.2
Time period
1996-2003 35 24.3 1 Reference 27.3 18.1-33.1
2004-2011 67 29.3 1.00 0.60-1.67 0.99 27.4 19.4-31.4
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emphasized during regular internal teaching sessions
when bloodstream infection or endocarditis was being
reviewed.
Our study has several limitations. It is carried out in a
single Norwegian region and the results are not neces-
sarily representative for other geographic areas. We do
however believe that it could be representative of the
situation in many other local hospitals of similar size.
The positive blood cultures were prospectively registered
by our microbiology laboratory, but the clinical informa-
tion was retrieved from the hospital records at a later
date, which is inferior to standardized prospective clin-
ical registration. The assignment of focus of infection
was largely based on clinical assessments and investiga-
tions carried out at the time of patient admission. Theinvestigations were carried out at the discretion of the
treating clinician, and as such the diagnostic accuracy
may have varied between patients. However, this data
reflects the clinical everyday management and decision
basis that were available for these patients. All the data
were not available for all the patients, especially during
the earlier part of the study and regarding antibiotic
management. However, this design confers a greater
level of detail and accuracy than observational studies
based on discharge data.
Conclusions
Despite great efforts to improve survival of sepsis the
last decade, there was no reduction in case fatality rate
during the study period. There have been some promis-
ing results both of infectious disease consultation of all
Paulsen et al. BMC Infectious Diseases  (2015) 15:116 Page 9 of 10patients with Staphylococcus aureus bacteremia [38-40]
and implementation of Quality of Care bundles for the
management of these patients [41,42]. These types of
initiatives along with improved measures of prevention,
diagnosis and management will hopefully help improve
the outcome of Staphylococcus aureus bloodstream in-
fection in the future.
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